MARKET

MYMD

MYMD

MyMD Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.49
+0.70
+10.31%
After Hours: 7.50 +0.01 +0.13% 17:04 09/17 EDT
OPEN
6.79
PREV CLOSE
6.79
HIGH
7.54
LOW
6.73
VOLUME
486.61K
TURNOVER
--
52 WEEK HIGH
10.48
52 WEEK LOW
3.300
MARKET CAP
279.92M
P/E (TTM)
-4.0835
1D
5D
1M
3M
1Y
5Y
MyMD Pharma to Start Mid-Stage MYMD-1 Trial to Delay Aging
MT Newswires · 4d ago
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation Of Phase 2 Clinical Trial Of MYMD-1 For Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate
Benzinga · 4d ago
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
BALTIMORE, September 13, 2021--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of M...
Business Wire · 4d ago
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
BALTIMORE, September 09, 2021--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Wainwright 23rd Annual Global Investment Conferenc...
Business Wire · 09/09 14:15
BRIEF-MyMD Pharmaceuticals Announces Issuance Of U.S. Patent For Use Of Lead Candidate Mymd-1 For Treating Fibrosis And Asthma
reuters.com · 08/24 14:24
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
BALTIMORE, August 24, 2021--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the U...
Business Wire · 08/24 14:17
MyMD Pharmaceuticals Granted U.S. Patent Titled 'Method of treating disorders associated with chronic inflammation'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6593&f=G&l=50&d=PTXT&p=132&S1=20210824&OS=20210824&RS=20210824
Benzinga · 08/24 13:40
MyMD Pharmaceuticals Secures US Patent for Asthma, Fibrosis Treatment
MT Newswires · 08/24 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYMD. Analyze the recent business situations of MyMD Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYMD stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 4.94M
% Owned: 13.23%
Shares Outstanding: 37.37M
TypeInstitutionsShares
Increased
11
3.64M
New
6
684.58K
Decreased
0
0
Sold Out
6
199.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Chairman/Lead Director/Independent Director
Joshua Silverman
President/Director
Chris Chapman
Chief Financial Officer
Ian Rhodes
Executive Vice President/General Counsel
Paul Rivard
Chief Scientific Officer
Adam Kaplin
Director
Craig Eagle
Director
Jude Uzonwanne
Independent Director
Bill White
No Data
About MYMD
MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Webull offers kinds of MyMD Pharmaceuticals Inc stock information, including NASDAQ:MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.